Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | TMPRSS2 | O15393 | 5/20 | 0.50 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | NAMPT | P43490 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.48 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.48 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22493880 | 0.82 | TMPRSS2 (0.57) | TMPRSS2L3MBTL3NAMPTSMN1; SMN2NPC1 | |
| SCHEMBL22493893 | 0.81 | LMNA (0.59) | LMNAKDM4ETMPRSS2L3MBTL3NAMPT | |
| SCHEMBL20873106 | 0.77 | TRPV1 (0.67) | LMNATMPRSS2NAMPTSMN1; SMN2NPC1 | |
| SCHEMBL20873129 | 0.77 | TMPRSS2 (0.48) | LMNAKDM4ETMPRSS2L3MBTL3ALDH1A1 | |
| SCHEMBL4795400 | 0.76 | HSD17B3 (0.67) | LMNATMPRSS2L3MBTL3ALDH1A1NAMPT | |
| SCHEMBL20873126 | 0.76 | KCNK3 (0.54) | TMPRSS2L3MBTL3NAMPTSMN1; SMN2NPC1 | |
| SCHEMBL23844169 | 0.76 | LMNA (0.76) | LMNAKDM4EALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL8225940 | 0.76 | NAMPT (0.50) | NAMPT | |
| SCHEMBL10024974 | 0.75 | SMN1; SMN2 (0.49) | LMNAKDM4EL3MBTL3ALDH1A1NAMPT | |
| SCHEMBL20873112 | 0.75 | NAMPT (0.49) | LMNAKDM4ETMPRSS2L3MBTL3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464289-B1 | ULTRA-POTENT VINCA ALKALOIDS: ADDED MOLECULAR COMPLEXITY FURTHER DISRUPTS THE TUBULIN DIMER-DIMER INTERFACE | SCRIPPS RESEARCH INST (US) | 2021-04-21 | — | — | EP | disclosed |
| US-10975101-B2 | Ultra-potent vinca alkaloids: added molecular complexity further disrupts the tublin dimer-dimer interface | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-04-13 | — | — | US | disclosed |
| US-20200317696-A1 | ULTRA-POTENT VINA ALKALOIDS: ADDED MOLECULAR COMPLEXITY FURTHER DISRUPTS THE TUBLIN DIMER-DIMER INTERFACE | NATIONAL INSTITUTES OF HEALTH | 2020-10-08 | — | — | US | disclosed |
| EP-3464289-A1 | ULTRA-POTENT VINA ALKALOIDS: ADDED MOLECULAR COMPLEXITY FURTHER DISRUPTS THE TUBLIN DIMER-DIMER INTERFACE | The Scripps Research Institute (US) | 2019-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975101-B2 | Ultra-potent vinca alkaloids: added molecular complexity further disrupts the tublin dimer-dimer interface | TUBA1C, TUBB2A, TUBA1A | LMNA 3125/4885KDM4E 3798/4885TMPRSS2 3789/4885 |
| US-20200317696-A1 | ULTRA-POTENT VINA ALKALOIDS: ADDED MOLECULAR COMPLEXITY FURTHER DISRUPTS THE TUBLIN DIMER-DIMER INTERFACE | TUBA1A, TUBA1C, TUBB2A | LMNA 2802/4885KDM4E 3842/4885TMPRSS2 3827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.